AbbVie Debt to Equity Ratio 2010-2024 | ABBV

Current and historical debt to equity ratio values for AbbVie (ABBV) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. AbbVie debt/equity for the three months ending September 30, 2024 was 8.51.
AbbVie Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-09-30 $0.00B 0.00
2024-06-30 $135.12B $6.82B 19.81
2024-03-31 $140.83B $8.05B 17.50
2023-12-31 $124.31B $10.40B 11.96
2023-09-30 $124.09B $12.13B 10.23
2023-06-30 $122.47B $12.90B 9.50
2023-03-31 $121.24B $13.30B 9.11
2022-12-31 $121.52B $17.29B 7.03
2022-09-30 $125.30B $16.03B 7.82
2022-06-30 $128.50B $14.69B 8.75
2022-03-31 $126.90B $16.31B 7.78
2021-12-31 $131.09B $15.44B 8.49
2021-09-30 $135.28B $13.58B 9.96
2021-06-30 $135.38B $12.59B 10.75
2021-03-31 $136.77B $13.73B 9.96
2020-12-31 $137.47B $13.10B 10.50
2020-09-30 $134.33B $15.29B 8.79
2020-06-30 $134.80B $14.73B 9.15
2020-03-31 $98.61B $-7.42B -13.30
2019-12-31 $97.29B $-8.17B -11.91
2019-09-30 $67.67B $-8.23B -8.23
2019-06-30 $65.71B $-8.57B -7.67
2019-03-31 $64.60B $-7.83B -8.25
2018-12-31 $67.80B $-8.45B -8.03
2018-09-30 $69.09B $-2.92B -23.65
2018-06-30 $65.02B $-3.38B -19.26
2018-03-31 $65.79B $3.55B 18.52
2017-12-31 $65.69B $5.10B 12.89
2017-09-30 $62.15B $6.69B 9.30
2017-06-30 $60.99B $6.01B 10.15
2017-03-31 $60.67B $5.00B 12.14
2016-12-31 $61.46B $4.64B 13.26
2016-09-30 $60.16B $6.47B 9.30
2016-06-30 $61.57B $5.64B 10.92
2016-03-31 $49.08B $4.64B 10.57
2015-12-31 $49.11B $3.95B 12.45
2015-09-30 $49.97B $4.86B 10.28
2015-06-30 $48.35B $5.50B 8.79
2015-03-31 $25.32B $1.38B 18.39
2014-12-31 $25.77B $1.74B 14.79
2014-09-30 $23.81B $4.65B 5.13
2014-06-30 $23.83B $5.22B 4.57
2014-03-31 $23.96B $4.70B 5.10
2013-12-31 $24.71B $4.49B 5.50
2013-09-30 $24.68B $3.58B 6.90
2013-06-30 $24.35B $3.56B 6.84
2013-03-31 $24.21B $2.96B 8.19
2012-12-31 $23.65B $3.36B 7.03
2012-09-30 $7.06B $15.67B 0.45
2012-06-30 $6.20B $11.51B 0.54
2012-03-31 $6.91B $12.05B 0.57
2011-12-31 $7.59B $11.93B 0.64
2011-09-30 $0.00B $0.00B 0.00
2011-06-30 $0.00B $0.00B 0.00
2011-03-31 $0.00B $0.00B 0.00
2010-12-31 $5.43B $15.70B 0.35
2009-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $359.539B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Novo Nordisk (NVO) Denmark $502.334B 38.34
Johnson & Johnson (JNJ) United States $385.533B 15.64
Merck (MRK) United States $258.042B 17.12
Novartis AG (NVS) Switzerland $223.511B 14.86
AstraZeneca (AZN) United Kingdom $221.444B 19.73
Pfizer (PFE) United States $159.177B 10.89
Sanofi (SNY) $135.190B 12.25
Innoviva (INVA) United States $1.205B 6.69